Soft-Tissue Tumors: Value of Static and Dynamic Gadopentetate Dimeglumine–enhanced MR Imaging in Prediction of Malignancy

Abstract

Static and dynamic contrast-enhanced MR imaging, when added to nonenhanced MR imaging, improved differentiation between benign and malignant soft-tissue lesions.

Short-term follow-up MRI after unplanned resection of malignant soft-tissue tumours; quantitative measurements on dynamic contrast enhanced and diffusion-weighted MR images

“…12 Changes in enhancement patterns using TCC provide information on the vascular pharmacokinetics of tumours, which can be assessed qualitatively by characterizing enhancement patterns or quantitatively by calculating various pharmacokinetic parameters. 20 K ep is defined as the ratio of transfer constant to EES (K ep 5 K trans /V e ). K trans has several physiologic interpretations that depend on the balance between capillary permeability and blood flow in the tissue of interest.…”

MR Evaluation of Sinonasal Angiomatous Polyp

“…It was reported in recent studies on DCE MR imaging that this selection of ROI could better reflect the hemodynamic alterations of the lesion. [19][20][21] Hence, the TIC pattern should serve only as a diagnostic clue for reference until further studies of DCE MR imaging in this and other sinonasal masses can be performed.…”

Musculoskeletal Tumors: How to Use Anatomic, Functional, and Metabolic MR Techniques

“…Perfusion imaging sequences are used for providing insight into the vascularity of a tumor and can be accomplished with a variety of pulse sequences, including DW sequences (31), unenhanced perfusion sequences (60,61), and the most commonly implemented dynamic contrastenhanced sequence (62)(63)(64)(65)(66)(67)(68)(69)(70)(71)(72)(73)(74)(75)(76)(77)(78)(79)(80). Perfusion imaging with dynamic contrast-enhanced MR imaging is the most popular technique at this time, since other techniques have not been well explored for musculoskeletal tumors.…”

“…Therefore, observation of the pattern of enhancement over time on a time-intensity curve provides insight into the vascular pharmacokinetics of a tumor that can be assessed qualitatively (with characterization of the enhancement pattern) or quantitatively (with calculation of various pharmacokinetic parameters such as the mean arterial slope or the time to peak enhancement) (73,76,77,84). Distinguishing patterns of enhancement that have been associated with benign and malignant musculoskeletal lesions (77,81,84,85), mainly by assessing the first-pass kinetics. Malignant lesions generally show early rapid enhancement (Fig 2e) and higher slopes of arterial enhancement compared with benign lesions, although this pattern is not entirely specific, as shown in Figure 5.…”